

Date: February 06, 2026

To,  
National Stock Exchange of India Ltd,  
Exchange Plaza, 5th Floor, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

Company Symbol: DENTALKART, ISIN: INE0N5801013

**Sub: Outcome of the meeting of the Board of Directors of VASA DENTICITY LIMITED (the “Company”) held on Friday, February 6, 2026, and submission of Un-audited Standalone and Consolidated Financial Results for the Quarter and nine month ended December 31, 2025**

**Ref: Reg. 30 and Reg. 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)**

Respected Sir/ Madam,

Pursuant to the provisions of Regulation 30, Regulation 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR’), we wish to inform you that the Board of Directors (the ‘Board’) of Vasa Denticity Limited at its meeting held today i.e., Friday, February 6, 2026 have inter-alia considered and approved:

1. **Unaudited Standalone and Consolidated Financial Results along with Limited Review Report received from the auditors of the company for the quarter and nine months ended on December 31, 2025. (enclosed with this letter)**

Further, pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015 and SEBI Circular No. CIR/CFD/CMD56/2016 dated May 27, 2016, we hereby declare that the Statutory Auditors of the Company, M/s KRA & Co., Chartered Accountants (FRN: 020266N), have expressed an Un-modified opinion in respect of the Financial Results of the company for the quarter and nine month ended December 31, 2025. The same has been attached as **ANNEXURE-A**

Further, pursuant to Regulation 30(8) of the Listing Regulations the enclosed disclosures will be made available on the company’s website at: [www.dentalkart.com](http://www.dentalkart.com)

2. **Appointment of M/S ASA & ASSOCIATES LLP (FRN: 009571N/N500006), Chartered Accountants, as an Internal Auditor of the Company for financial year 2026-27 to conduct Internal Audit of the Company and to furnish the Internal Audit Report.**

Disclosure of information pursuant to Regulation 30 of the Listing Regulations and SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated 11th July 2023 is given under **ANNEXURE-B**.

The Board meeting of the company commenced at 03:00 P.M. and concluded at 04:35 P.M.

You are requested to take the above information on your records and disseminate the same on your website.

Thanking you,

**Yours sincerely,  
VASA Denticity Limited**

**NIDHI  
COMPANY SECRETARY & COMPLIANCE OFFICER  
MEMBERSHIP No: A74591**

Encl: a/a



**Independent Auditor's Review Report on Standalone Unaudited Quarter and Nine Months Financial Results of the Company pursuant to the regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of VASA DENTICITY LIMITED**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results ("the Statement") of **VASA DENTICITY LIMITED** ("the Company") for the quarter and Nine Months ended December 31, 2025 ('the Statement'), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulation').
2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25") prescribed under section 133 of the Companies Act 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of Securities and Exchange Board of India (Listing and Disclosure Requirements) Regulations, 2015. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For KRA & Co.**  
**Chartered Accountants**  
**(Firm Registration No.020266N)**

**SAURABH**  
**GARG**  
Digitally signed by  
SAURABH GARG  
Date: 2026.02.06  
16:34:24 +05'30'

**Saurabh Garg**  
**Partner**  
**Membership No.: 510541**  
**UDIN: 26510541JNTWDY8617**  
**Place: New Delhi**  
**Date: February 06, 2026**

**VASA DENTICITY LIMITED**

Regd. Office : KHASRA NO. 714, VILLAGE P.O. CHATTARPUR NEW DELHI SOUTH DELHI - 110074  
CIN: L74999DL2016PLC305052

Website: www.dentalkart.com Email: cs@dentalkart.com Tel: 91-8527360456

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS  
FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025**

(Amount in Rs. Lacs)

Sl. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	<b>Income</b>						
	a. Revenue from Operations	7,147.19	7,272.15	6,283.39	20,421.11	17,467.80	24,915.29
	b. Other Income	92.59	66.46	45.17	257.22	174.36	193.55
	<b>Total Income</b>	<b>7,239.78</b>	<b>7,338.61</b>	<b>6,328.56</b>	<b>20,678.33</b>	<b>17,642.16</b>	<b>25,108.84</b>
2	<b>Expenses</b>						
	a. Purchase of stock-in-trade	5,616.15	5,429.35	4,359.32	16,614.27	14,741.72	19,472.32
	b. Change in inventories of stock-in-trade	(462.76)	(550.55)	28.75	(2,589.16)	(2,124.49)	(1,966.98)
	c. Employee Benefits Expenses	578.19	564.24	393.84	1,659.44	1,004.58	1,428.66
	d. Finance Costs	9.98	-	-	9.98	0.05	0.05
	e. Depreciation and Amortisation Expenses	56.35	33.78	49.62	117.32	114.08	170.54
	f. Other Expenses	1,232.56	1,222.60	948.85	3,630.85	2,190.94	3,674.36
	<b>Total Expenses</b>	<b>7,030.47</b>	<b>6,699.42</b>	<b>5,780.38</b>	<b>19,442.70</b>	<b>15,926.88</b>	<b>22,778.95</b>
3	<b>Profit before exceptional and extraordinary items and</b>	<b>209.31</b>	<b>639.19</b>	<b>548.18</b>	<b>1,235.63</b>	<b>1,715.28</b>	<b>2,329.89</b>
4	Exceptional item	-	-	-	-	-	-
5	<b>Profit before extraordinary items and tax</b>	<b>209.31</b>	<b>639.19</b>	<b>548.18</b>	<b>1,235.63</b>	<b>1,715.28</b>	<b>2,329.89</b>
6	Extraordinary items	-	-	-	-	-	-
7	<b>Profit before tax</b>	<b>209.31</b>	<b>639.19</b>	<b>548.18</b>	<b>1,235.63</b>	<b>1,715.28</b>	<b>2,329.89</b>
8	<b>Tax expense</b>						
	a. Current Tax	52.62	128.16	148.37	280.55	447.60	632.78
	c. Deferred Tax	1.10	12.09	1.29	13.09	(9.38)	(11.81)
	d. Earlier year taxes	-	-	-	-	-	-
	<b>Total tax expense</b>	<b>53.72</b>	<b>140.25</b>	<b>149.66</b>	<b>293.64</b>	<b>438.22</b>	<b>620.97</b>
9	<b>Profit after tax</b>	<b>155.59</b>	<b>498.94</b>	<b>398.52</b>	<b>941.99</b>	<b>1,277.06</b>	<b>1,708.92</b>
10	<b>Paid-up Equity Share Capital (Face value of Rs.10 each)</b>	<b>1,733.68</b>	<b>1,733.68</b>	<b>1,662.17</b>	<b>1,733.68</b>	<b>1,662.17</b>	<b>1,662.17</b>
11	<b>Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year</b>	<b>10,351.73</b>	<b>10,351.73</b>	<b>5,233.05</b>	<b>10,351.73</b>	<b>5,233.05</b>	<b>5,233.05</b>
12	<b>Earnings Per Share (Face value of Rs. 10/- each)</b>						
	Basic (in Rs.) (not annualised)	0.90	2.95	2.45	5.56	7.93	10.53
	Diluted (in Rs.) (not annualised)	0.90	2.95	2.45	5.56	7.93	10.53

**Notes:-**

- The above financial results for the Quarter and Nine months ended December 31, 2025 have been reviewed by Audit committee and approved by the Board of Directors in their respective meetings held on February 06, 2026
- The Company is engaged primarily in the business of trading dental products on PAN India basis. Accordingly, there are no separate reportable segments as per
- The financial result has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard (AS) prescribed under section
- Figures for the previous year have been re-grouped/ rearranged/ restated wherever necessary to make them comparable with those of the current year.
- Supply Chain Realignment: Implementation of the Customs (Voluntary Revision) Regulations, 2025 caused industry-wide clearance delays for proprietary imports.
- Forex Headwinds: Significant depreciation of the Indian Rupee (INR) increased the landed cost of imports during the quarter. The Q3 margin compression is temporary. Management has already initiated corrective measures to streamline custom clearances and mitigate forex impact. We anticipate a rebound in profitability in the near term.

Place: New Delhi  
Date: 06.02.2026

For VASA DENTICITY LIMITED.

  
 7  
 Vikas Agarwal  
 Managing Director  
 DIN -07487686



**Independent Auditor's Review Report on Consolidated Unaudited Quarter and Nine Months Financial Results of the Company pursuant to the regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of VASA DENTICITY LIMITED**

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of **VASA DENTICITY LIMITED** (‘the Holding Company’) and its subsidiary (the Holding Company and its subsidiary constitute “the Group”) for the quarter and nine months ended December 31, 2025 (‘the Statement’), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘Listing Regulation’).
2. This Statement which is the responsibility of the Holding Company’s Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 “Interim Financial Reporting” (“AS 25”) prescribed under section 133 of the Companies Act 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of Securities and Exchange Board of India (Listing and Disclosure Requirements) Regulations, 2015. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company’s personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entity:
  - i. Waldent Innovations Private Limited
  - ii. Smileworks Private Limited
  - iii. Dentalkart Distribution UK Limited
5. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in

the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

#### **Other Matter**

6. We did not review the interim financial information of one subsidiary whose interim financial information for the nine months ended December 31, 2025, reflects total revenue of Rs. 204.36 Lakhs, total net loss after tax of Rs. 60.21 Lakhs, total assets of Rs. 532.37 Lakhs and net cash outflow of Rs. 17.71 Lakhs This interim financial information has been reviewed by other auditor whose report has been furnished to us by the Holding management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.
7. We did not review the interim financial information of one subsidiary whose interim financial information for the nine months ended December 31, 2025, reflects total revenue of Rs. Nil, total net loss after tax of Rs. Nil, total assets of Rs. 122.65 Lakhs and net cash inflow of Rs. 122.65 Lakhs This interim financial information has not been reviewed by the auditors and this subsidiary has been consolidated based on their management certified accounts.

Our conclusion is not modified in respect of this matter.

**For KRA & Co.**  
**Chartered Accountants**  
**(Firm Registration No.020266N)**

**SAURABH GARG** Digitally signed  
by SAURABH  
GARG  
Date: 2026.02.06  
16:33:38 +05'30'

**Saurabh Garg**  
**Partner**  
**Membership No.: 510541**  
**UDIN: 26510541ZBANYL7331**  
**Place: New Delhi**  
**Date: February 06, 2026**

**VASA DENTICITY LIMITED**  
 Regd. Office : KHASRA NO. 714, VILLAGE P.O. CHATTARPUR NEW DELHI SOUTH DELHI - 110074  
 CIN: L74999DL2016PLC305052

Website: www.dentalkart.com Email: cs@dentalkart.com Tel: 91-8527360456

**STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS  
 FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025**


(Amount in Rs. Lacs)

Sl. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	<b>Income</b>						
	a Revenue from Operations	7,215.66	7,294.31	6,283.39	20,561.26	17,467.80	24,936.57
	b Other Income	88.48	63.26	45.17	247.58	174.36	193.55
	<b>Total Income</b>	<b>7,304.14</b>	<b>7,357.57</b>	<b>6,328.56</b>	<b>20,808.84</b>	<b>17,642.16</b>	<b>25,130.12</b>
2	<b>Expenses</b>						
	a Cost of Material Consumed	40.20	64.00	-	104.20	-	-
	b Purchase of stock-in-trade	5,609.20	5,342.74	4,359.32	16,562.89	14,741.72	19,481.71
	c Change in inventories of stock-in-trade	(462.76)	(531.89)	28.75	(2,589.16)	(2,124.49)	(1,978.37)
	d Employee Benefits Expenses	607.79	597.10	393.84	1,747.81	1,004.58	1,444.68
	e Finance Costs	9.98	0.05	-	10.03	0.05	0.92
	f Depreciation and Amortisation Expenses	65.41	42.68	49.62	141.28	114.08	172.86
	g Other Expenses	1,246.47	1,238.15	948.93	3,672.64	2,192.37	3,696.26
	<b>Total Expenses</b>	<b>7,116.29</b>	<b>6,752.83</b>	<b>5,780.46</b>	<b>19,649.69</b>	<b>15,928.31</b>	<b>22,818.06</b>
3	<b>Profit before exceptional and extraordinary items and</b>	<b>187.85</b>	<b>604.74</b>	<b>548.10</b>	<b>1,159.15</b>	<b>1,713.85</b>	<b>2,312.06</b>
4	Exceptional item	-	-	-	-	-	-
5	<b>Profit before extraordinary items and tax</b>	<b>187.85</b>	<b>604.74</b>	<b>548.10</b>	<b>1,159.15</b>	<b>1,713.85</b>	<b>2,312.06</b>
6	Extraordinary items	-	-	-	-	-	-
7	<b>Profit before tax</b>	<b>187.85</b>	<b>604.74</b>	<b>548.10</b>	<b>1,159.15</b>	<b>1,713.85</b>	<b>2,312.06</b>
8	<b>Tax expense</b>						
	a Current Tax	52.62	128.16	148.37	280.55	447.60	632.78
	c Deferred Tax	1.10	12.09	1.29	13.09	(9.14)	(10.53)
	d Earlier year taxes	-	-	-	-	-	-
	<b>Total tax expense</b>	<b>53.72</b>	<b>140.25</b>	<b>149.66</b>	<b>293.64</b>	<b>438.46</b>	<b>622.25</b>
9	<b>Profit after tax</b>	<b>134.13</b>	<b>464.49</b>	<b>398.44</b>	<b>865.51</b>	<b>1,275.39</b>	<b>1,689.81</b>
	Less: Minority Interest	(3.17)	(12.96)	-	(24.08)	-	(6.95)
10	<b>Profit For the year</b>	<b>137.30</b>	<b>477.45</b>	<b>398.44</b>	<b>889.59</b>	<b>1,275.39</b>	<b>1,696.76</b>
11	<b>Paid-up Equity Share Capital (Face value of Rs.10</b>	<b>1,733.68</b>	<b>1,733.68</b>	<b>1,662.17</b>	<b>1,733.68</b>	<b>1,662.17</b>	<b>1,662.17</b>
12	<b>Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year</b>						
		<b>10,339.35</b>	<b>10,339.35</b>	<b>5,232.84</b>	<b>10,339.35</b>	<b>5,232.84</b>	<b>5,232.84</b>
13	<b>Earnings Per Share (Face value of Rs. 10/- each)</b>						
	Basic (in Rs.) (not annualised)	0.79	2.83	2.45	5.25	7.92	10.45
	Diluted (in Rs.) (not annualised)	0.79	2.83	2.45	5.25	7.92	10.45

**Notes:-**

- The above financial results for the Quarter and Nine months ended December 31, 2025 have been reviewed by Audit committee and approved by the Board of Directors in their respective meetings held on February 06, 2026
- The group is engaged primarily in the business of trading dental products on PAN India basis. Accordingly, there are no separate reportable segments as per Accounting Standard 17 - "Segment Reporting"
- The financial result has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard (AS) prescribed under section 133 of the Companies Act 2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.
- Figures for the previous year have been re-grouped/ rearranged/ restated wherever necessary to make them comparable with those of the current year.
- Supply Chain Realignment: Implementation of the Customs (Voluntary Revision) Regulations, 2025 caused industry-wide clearance delays for proprietary imports.
- Forex Headwinds: Significant depreciation of the Indian Rupee (INR) increased the landed cost of imports during the quarter. The Q3 margin compression is temporary. Management has already initiated corrective measures to streamline custom clearances and mitigate forex impact. We anticipate a rebound in profitability in the near term.

Place: New Delhi  
 Date: 06.02.2026

For VASA DENTICITY LIMITED.  
  
**Vikas Agarwal**  
 Managing Director  
 DIN -07487686

### ANNEXURE B

**Disclosure of information pursuant to Regulation 30 of the Listing Regulations and SEBI  
Circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated 11th July 2023**

S. No	Particulars	Details
1.	Reason for Change Viz., appointment, <del>resignation,</del> <del>removal, death or otherwise</del>	Appointment: In compliance with the section 138 of Companies Act 2013 and the requirements under SEBI Listing Regulations
2.	Date of appointment/ <del>re appointment/cessation</del> —(as applicable) & term of appointment/ <del>reappointment</del> ;	<b>Date: February 06, 2026</b>  <b>M/S ASA &amp; ASSOCIATES LLP</b> (FRN: 009571N/N500006), Chartered Accountants, as an Internal Auditor of the Company to carry out Internal Audit of the Company for a Financial Year 2026-2027.
3.	Brief profile (in case of appointment)	<b>Name of the Auditor:</b> ASA & Associates, LLP  <b>Office Address:</b> Aurobindo Tower, 81/1, Third Floor, Adchini, Aurobindo Marg, New Delhi - 110017  <b>Email:</b> Gaurav.bhatia@asa.in  <b>Terms of appointment:</b> To conduct Internal Audit for a Financial Year 2026-27.  <b>About the auditor:</b> ASA & Associates LLP (FRN: 009571N/N500006), Chartered Accountants, a member firm of Baker Tilly International, is one of India's top ten accounting and consulting firms.  The firm offers a comprehensive range of professional services, including accounting and business support, assurance, taxation, business advisory, risk advisory, cyber security, and transaction advisory (both buy-side and sell-side). With a strong PAN-India presence and access to Baker Tilly's global network, ASA & Associates serves clients across various sectors such as banking, finance, aviation, and manufacturing.  The firm is supported by a team of over 1,200 professionals and 70 partners, backed by more than 6,000 experts worldwide, ensuring reliable, high-quality, and innovative professional services.
4.	Disclosure of relationships between directors (in case of Appointment of a director).	Not Applicable